Incyte Announces Agreement To Acquire Medicxi-Backed Villaris Therapeutics And Auremolimab (Vm6), An Anti-Il-15Rβ Monoclonal Antibody
Acquiring Company
Incyte Dermatology
Acquired Company
Villaris
Description
Incyte (NASDAQ:INCY) today announced that the Company has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo. Its lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in 2023.
Quick answer
Incyte Dermatology is acquiring Villaris and Auremolimab, announced October 3, 2022.
- How much did Incyte Dermatology pay for Villaris?
- The deal value was not disclosed.
- What does Incyte Dermatology do?
- Incyte’s science-first approach and expertise in immunology has formed the foundation of the company.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Atossa Therapeutics, Inc. To Acquire Stake In Privately Held Dynamic Cell Therapies As Part Of Overall Car-T Strategy (November 1, 2022)
- Lilly To Acquire Akouos To Discover And Develop Treatments For Hearing Loss (October 18, 2022)
- Pfizer Completes Acquisition Of Global Blood Therapeutics (October 5, 2022)
- Collagen Matrix Acquires Polyganics (October 5, 2022)
- Pfizer Completes Acquisition Of Biohaven Pharmaceuticals (October 3, 2022)
- Solid Biosciences Announces Acquisition Of Aavantibio And Concurrent $75 Million Private Placement, $75M (September 30, 2022)
Who to call at Incyte Dermatology, and when
When Incyte Dermatology changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Incyte Dermatology raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Incyte Dermatology, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Incyte Dermatology. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Incyte Dermatology makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Villaris?
Villaris was acquired by Incyte Dermatology. The deal was reported on October 3, 2022. Incyte’s science-first approach and expertise in immunology has formed the foundation of the company. Incyte Dermatology is privately held and operates in Biotechnology.
When did Incyte Dermatology acquire Villaris?
Incyte Dermatology's acquisition of Villaris was reported on October 3, 2022. Incyte (NASDAQ:INCY) today announced that the Company has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Villaris do?
Based in Cary, North Carolina, Villaris was founded in 2019 by Medicxi and John Harris, M.D., Ph.D. to develop a potentially transformational new treatment to improve the lives of people living with vitiligo. It is privately held.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.